Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
Ulrich Ronellenfitsch(University of Mannheim), Johannes A. Vey(Heidelberg University), Jan van Lanschot(Erasmus MC Cancer Institute), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Bryan Burmeister(Princess Alexandra Hospital), Marc Ychou(Université de Montpellier), Patrick Michl(Heidelberg University), Jörg Kleeff(University Hospital in Halle), Maurizio Grilli(Heidelberg University), Tanja Proctor(Heidelberg University), Dirk Vordermark(Universitätsklinik für Strahlentherapie), Qian Shi(Mayo Clinic), Florian Lordick(Leipzig University), Fredrik Klevebro(Karolinska University Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Gary Alan Bass(University of Pennsylvania), David Cunningham(Royal Marsden NHS Foundation Trust), Matthew Nankivell(MRC Clinical Trials Unit at UCL), Meinhard Kieser(Heidelberg University), Manfred P. Lutz(Universitätsklinikum des Saarlandes), Svenja Seide(Heidelberg University), Ben M. Eyck(Erasmus MC Cancer Institute), Emilie Barbier(Université de Bourgogne), Magnus Nilsson(Karolinska University Hospital), Susan G. Urba(University of Michigan), Manish A. Shah(NewYork–Presbyterian Hospital), Christoph Michalski(Heidelberg University), Murielle Mauer(Heidelberg University), Juliane Friedrichs(Martin Luther University Halle-Wittenberg), Michael Stahl(Kliniken Essen-Mitte), T. N. Walsh(Connolly Hospital Blanchardstown)
Cited by 13
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k